Novartis Investigative Site

Adana, Yuregir 01250

2 studies enrolling now · 7 studies all time

What they study most

Atherosclerotic Cardiovascular Disease, Differentiated Thyroid Cancer (DTC), Early Breast Cancer, Metastatic Pancreatic Ductal Adenocarcinoma, Ovarian Cancer, Sickle Cell Disease

Studies at this site

• A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease — Recruiting now
• Phase IIIb Study of Ribociclib + ET in Early Breast Cancer — Recruiting now
• Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study — Recruiting now
• Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease — Running, not enrolling
• Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer — Running, not enrolling
• Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected — Stopped early
• Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2 — Completed